Reeves J H, Russell G M, Cade J F, McDonald M
Intensive Care Unit, Royal Melbourne Hospital, Victoria, Australia.
Chest. 1989 Dec;96(6):1292-7. doi: 10.1378/chest.96.6.1292.
Ceftriaxone is a new, third-generation cephalosporin that, because of its long half-life, offers potential advantages of cost and convenience over similar agents such as cefotaxime. We compared the two drugs in a prospective, randomized study of the treatment of chest infections in seriously ill patients. Fifty-one patients (90 percent of whom were mechanically ventilated) received either ceftriaxone, 2g IV once daily, or cefotaxime, 2 g IV thrice daily, for five days. The two groups of patients appeared demographically comparable. Ceftriaxone in a single daily dose of 2 g once daily may not be satisfactory for the treatment of serious chest infections.
头孢曲松是一种新型的第三代头孢菌素，由于其半衰期长，与头孢噻肟等同类药物相比，在成本和便利性方面具有潜在优势。我们在一项针对重症患者胸部感染治疗的前瞻性随机研究中对这两种药物进行了比较。51例患者（其中90%接受机械通气）接受了为期5天的治疗，一组患者每日静脉注射一次2g头孢曲松，另一组患者每日静脉注射三次2g头孢噻肟。两组患者在人口统计学上似乎具有可比性。每日单次剂量2g的头孢曲松可能不足以有效治疗严重的胸部感染。
